These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22956860)

  • 1. The molecular profile of luminal B breast cancer.
    Creighton CJ
    Biologics; 2012; 6():289-97. PubMed ID: 22956860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer.
    Gao Y; Jones A; Fasching PA; Ruebner M; Beckmann MW; Widschwendter M; Teschendorff AE
    Clin Epigenetics; 2015; 7():126. PubMed ID: 26664652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
    Cornen S; Guille A; Adélaïde J; Addou-Klouche L; Finetti P; Saade MR; Manai M; Carbuccia N; Bekhouche I; Letessier A; Raynaud S; Charafe-Jauffret E; Jacquemier J; Spicuglia S; de The H; Viens P; Bertucci F; Birnbaum D; Chaffanet M
    PLoS One; 2014; 9(1):e81843. PubMed ID: 24416132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtyping of male breast cancer by immunohistochemistry.
    Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
    Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
    Izadi P; Mehrdad N; Foruzandeh F; Reza NM
    Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-190b Targets RFWD3 in Estrogen Receptor-Positive Breast Cancer.
    Frick EA; Kristjansdottir K; Ragnarsdottir S; Vilhjalmsson AI; Bustos MR; Vidarsdottir L; Gudjonsson T; Sigurdsson S
    Breast Cancer (Auckl); 2024; 18():11782234241234771. PubMed ID: 38504674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
    PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
    Tamimi RM; Baer HJ; Marotti J; Galan M; Galaburda L; Fu Y; Deitz AC; Connolly JL; Schnitt SJ; Colditz GA; Collins LC
    Breast Cancer Res; 2008; 10(4):R67. PubMed ID: 18681955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists.
    Johnson KS; Conant EF; Soo MS
    J Breast Imaging; 2021 Jan; 3(1):12-24. PubMed ID: 38424845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Collins LC; Cole KS; Marotti JD; Hu R; Schnitt SJ; Tamimi RM
    Mod Pathol; 2011 Jul; 24(7):924-31. PubMed ID: 21552212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD; Collins LC; Hu R; Tamimi RM
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
    Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
    Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
    Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
    Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
    Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
    Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.